Dr. Andrew Geall is the Chief Development Officer at Replicate Bioscience and cofounder of the company. Dr. Geall has over 20 years of professional experience in the development of drug delivery systems and is a pioneer in the fields of mRNA vaccines and nucleic acid delivery.
He is also Chief Scientific Officer at Precision NanoSystems Inc. (PNI). Here, he is focused on the creation of transformative nanoparticle medicines using their proprietary LNP delivery systems and microfluidic formulation platform.
Prior to joining Replicate Bioscience, he was Vice President of Formulations, Analytics and Chemistry at Avidity Biosciences, where he pioneered the development of their antibody-oligonucleotide conjugate delivery platform. As a member of the Executive Management, he helped raise over $100 million in venture capital and take the company public in June 2020 with an initial public stock offering of $259 million.
Prior to Avidity, he led mRNA vaccines the Vaccine division of Novartis. Over 7 years, he created a global team and was Principal Investigator on a Defense Advanced Research Project Agency (DARPA) contract to develop self-amplifying mRNA vaccines. Dr. Geall also had a two-year tenure at Novartis Pharmaceuticals AG, where he was the Global siRNA Formulation Team Leader, responsible for the design and implementation of the siRNA delivery strategy.
Dr. Geall received his pharmacy degree from the University of Bath in the UK and went on to do his pre-registration training, as a hospital Pharmacist, in the aseptic dispensing unit at St Helens and Knowsley Trust Hospitals. He then obtained his Ph.D. at the University of Bath in non-viral gene delivery.
Organization Name | Title At Company | Start Date | End Date | |
---|---|---|---|---|
Avidity Biosciences | Vice President of Formulations and Chemistry | Jan 1, 2015 | — | Detail |